A nurse-facilator intervention improved the use of β-blockers in outpatients with stable congestive heart failure

January 2004
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p22
Academic Journal
This article focuses on a study regarding the evaluation of strategies to increase β-blocker use in heart failure, published in the 2003 issue of the journal "Circulation." For this study 169 patients who met the criteria for congestive heart failure, and had left ventricular ejection fraction or moderate or severe left ventricular systolic dysfunction were examined. All providers received a provider education program. 25 providers with 54 patients were allocated to a nurse-facilitator group. More patients in the nurse-facilitator group were initiated or uptitrated on β-blockers and reached daily target β-blocker doses than in the provider- and patient-notification or control groups.


Related Articles

  • A nurse-facilator intervention improved the use of β-blockers in outpatients with stable congestive heart failure: COMMENTARY. Pugh, Jacqueline; Lawrence, Valerie // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p22 

    This article focuses on a study regarding the evaluation of strategies to increase β-blocker use in heart failure, published in the 2003 issue of the journal "Circulation." In the authors' opinion, the study shows that dedicating personnel to supervise specific treatment regimens is more...

  • Current use of beta adrenergic receptors blocking medication in paediatric heart failure. Slavík, Z. // Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Mar2012, Vol. 67 Issue 3, p192 

    Congenital heart disease and cardiomyopathy represent the most common cause of chronic congestive heart failure in children. To the contrary of published evidence from adult series, very little convincing evidence for clear clinical benefit of beta adrenergic receptors blocking medication exists...

  • Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or ... Waagstein, F.; Str�mblad, O.; Andersson, B.; B�hm, M.; Darius, M.; Delius, W.; Goss, F.; Osterziel, K.J.; Sigmund, M.; Trenkwalder, S.-P.; Wahlqvist, I. // European Journal of Heart Failure;Oct2003, Vol. 5 Issue 5, p679 

    Background: the effects of long-term administration of �-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart...

  • What doesn't kill you. Martindale, Diane // New Scientist;10/25/2003, Vol. 180 Issue 2418, p38 

    Dishing out drugs that make your symptoms worse seems like a rash, even dangerous way to treat patients. Miracle workers rarely come back for an encore, but in the world of heart medicine one little miracle is bucking the trend. Beta blockers were invented in 1964 and quickly became the most...

  • Beta-blockers in severe heart failure.  // Caribbean Health;Dec2001, Vol. 4 Issue 6, p19 

    The article discusses the clinical concept of beta-blockers. These benefit patients with mild or moderate heart failure. However, their effects on patients with severe heart failure are uncertain. With this, two large international trials have produced apparently conflicting results. The...

  • pindolol.  // Royal Society of Medicine: Medicines;2002, p440 

    The article presents information on pindolol which is a beta-blocker that can be used as an for raised blood pressure and as an treatment to relieve symptoms and improve exercise tolerance. Administration is oral. It is also available, as an antihypertensive treatment, in a compound preparation...

  • Are gene groups realjy predictive in the real world?  // Pulse;11/5/2005, Vol. 65 Issue 43, p25 

    Focuses on the need to modify treatment of myocardial infarction (MI) according to genetic variations. Ineffectiveness of beta blockers in certain gene groups; Citations of the chance of those patients with high risk of MI to die.

  • ... and for congestive heart failure.  // Consumer Reports on Health;Nov98, Vol. 10 Issue 11, p10 

    Reports on a study presented at a meeting of the European Society of Cardiology, which adds to the evidence that beta-blocker drugs can also reduce the risk of death in patients with mild to moderate heart failure by slowing the progression of the disease and reversing some cardiac damage.

  • β Adrenergic Blockers in Heart Failure: Review of Mechanisms of Action and Clinical Outcomes. Satwani, Shiyam; Dec, G. William; Narula, Jagat // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2004, Vol. 9 Issue 4, p243 

    Presents a review of the normal functioning of the Î’-adrenergic pathway, the consequences of hyperadrenergism on this crucial signaling pathway, and the mechanisms by which chronic Î’-blocker therapy reverses these abnormalities. Summary of the clinical evidence from controlled trials of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics